Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

11

Revenue 2017

AstraZeneca

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of AstraZeneca's 2013 sales performance.

Astra Zeneca

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer AstraZeneca’s Imjudo (tremelimumab) – an anti-CTLA4 antibody – in combination with Imfinzi (durvalumab) – an anti-PD-L1 antibody – has been approved by the US Food and Drug Administration (FDA) for the

New study identifies gene associated with strong immune response to COVID-19 vaccines

New study identifies gene associated with strong immune response to COVID-19 vaccines They also looked at DNA samples from children who had participated in clinical trials for the Oxford-AstraZeneca vaccine.

UK Government announces £800m boost to support innovation and improve patient safety

UK Government announces £800m boost to support innovation and improve patient safety The NIHR BRCs have supported almost 60, 000 experimental medicine research studies over the past nine years including the development of the Oxford AstraZeneca COVID-19 vaccine, as well as promising

AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma

AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma Tezspire demonstrated reduced annualised rate of asthma exacerbations. AstraZeneca’s (AZ) Tezspire (tezepelumab) has been granted marketing authorisation in Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA) for

EC approves Alexion's Ultomiris as generalised myasthenia gravis treatment

EC approves Alexion's Ultomiris as generalised myasthenia gravis treatment The European Commission (EC) has approved Aexion’s – part of the AstraZeneca Rare Disease group – Ultomiris (ravulizumab) in Europe as an add-on to standard therapy for generalised myasthenia gravis (gMG).

[ Previous 5 results ] 7 8 9 10 11 12 13 14 15 16 [ Next 5 results ]

Subscribe to our email news alerts

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...